FINANCE ROUNDUP: Will VC Be Last Man Standing If Biotech Bubble Bursts?
This article was originally published in Scrip
The bad news about the rapid rise in biotechnology company valuations? It will end eventually. The good news? While initial public offerings may no longer be an option for some pre-commercial companies to fund drug development, several venture capital investors recently raised new funds to back biotech startups and support follow-on financing rounds.
Register for our free email digests: